Blogging Journal San Diego Startup 
Xconomy
SEPTEMBER 27, 2016
Fortis Therapeutics, a new San Diego biotech, has raised $18 million in initial funding to develop drugs for hard-to-treat prostate and bone marrow cancers. San Diego’s Avalon Ventures led the Series A round, and has established Fortis at COI Pharma, the firm’s biotech incubator (which now houses 16 life sciences startups).
Xconomy
JUNE 12, 2018
He’s the CEO of San Diego medical device startup Tear Film Innovations, which recently raised a. Come to think of it, do your eyes feel dry? Some eye doctors are finding more cases of dry eye in young adults, and even children. That has Rob Thornill seeing opportunity.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
SEPTEMBER 2, 2016
Nobel Prize winner Roger Tsien, a UC San Diego chemist, passed away in Oregon this week. As the San Diego Union Tribune reported in 2013, Tsien (pictured) was also unafraid to shine the spotlight on what he considered suspect scientific approaches, even when espoused by legends like DNA co-discoverer James Watson.
Xconomy
MAY 24, 2018
The research, published in the journal Cell , indicate that several specific strains of bacteria work together in mice to provide neuroprotective effects against epileptic seizures.
Xconomy
JUNE 30, 2016
A key scientist involved in integrin research, Harvard University immunologist Tim Springer, is spinning out a biotech startup to develop a new generation of integrin-blocking drugs—pills instead of antibody-based injections—that he says will benefit from “a complete understanding” of these complex molecules.
Xconomy
JUNE 3, 2016
It was fitting this week that, in the lead-up to two of biomedicine’s biggest self-celebrations, we were served ample reminder of the industry’s expensive decisions gone wrong. Thousands of others will head to San Francisco for BIO, which has a distinct international flavor. Teva nabbed deutetrabenazine in its $3.2
Xconomy
AUGUST 16, 2016
A recent Wall Street Journal article that raised the possibility of Biogen as the target of another huge pharma buyout cited the lack of productivity as a major driver of M&A in the pharmaceutical industry. The authors made the point that, given the size of companies today, a single garden-variety blockbuster hardly moves the needle.
Expert insights. Personalized for you.
40 
Let's personalize your content